Therefore, these findings suggested that PCSK9 inhibition restores the potency of anti‐PD‐1 for MSS CRC therapy, indicating that a combination of PCSK9 inhibition and anti‐PD‐1 therapy may be a feasible therapy strategy for MSS CRC. Here, PDCD1 is linked to colorectal carcinoma.